PHILADELPHIA, Aug. 30, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it has commenced marketing Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL, an internally ...
Credit: Azurity Pharmaceuticals. Myhibbin is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection. Myhibbin is expected to be commercially available in the second ...
Lannett is offering mycophenolate mofetil for oral suspension, 200 mg/mL, an internally developed product. The medication is the generic of Roche Palo Alto’s CellCept. It is indicated for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results